Two Sigma Advisers
MRSN

Two Sigma Advisers’s Mersana Therapeutics MRSN Stock Holding History

Two Sigma Advisers’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,640
Closed -$315K – 2524
2025
Q3 		$315K Buy
40,640
+3,160
+8% +$23.7K ﹤0.01% 1966
2025
Q2 		$277K Buy
37,480
+27,152
+263% +$239K ﹤0.01% 1996
2025
Q1 		$88.9K Sell
10,328
-7,592
-42% -$117K ﹤0.01% 2255
2024
Q4 		$641K Sell
17,920
-1,552
-8% -$80.3K ﹤0.01% 1675
2024
Q3 		$920K Sell
19,472
-9,300
-32% -$410K ﹤0.01% 1452
2024
Q2 		$1.45M Buy
28,772
+22,540
+362% +$1.63M ﹤0.01% 1371
2024
Q1 		$698K Buy
6,232
+176
+3% +$17.5K ﹤0.01% 1729
2023
Q4 		$351K Sell
6,056
-8,372
-58% -$337K ﹤0.01% 2053
2023
Q3 		$458K Sell
14,428
-8,696
-38% -$413K ﹤0.01% 1822
2023
Q2 		$1.9M Sell
23,124
-9,056
-28% -$1.32M ﹤0.01% 1226
2023
Q1 		$3.31M Sell
32,180
-9,952
-24% -$1.4M 0.01% 1004
2022
Q4 		$6.17M Sell
42,132
-2,576
-6% -$435K 0.02% 696
2022
Q3 		$7.56M Buy
44,708
+1,240
+3% +$202K 0.02% 579
2022
Q2 		$5.02M Sell
43,468
-10,512
-19% -$989K 0.01% 775
2022
Q1 		$5.38M Buy
53,980
+11,972
+28% +$1.4M 0.01% 772
2021
Q4 		$6.53M Buy
42,008
+16,808
+67% +$3.27M 0.02% 655
2021
Q3 		$5.94M Buy
25,200
+2,496
+11% +$729K 0.02% 708
2021
Q2 		$7.71M Sell
22,704
-764
-3% -$289K 0.02% 662
2021
Q1 		$9.49M Buy
23,468
+3,872
+20% +$1.88M 0.03% 592
2020
Q4 		$13M Buy
19,596
+7,816
+66% +$4.35M 0.03% 479
2020
Q3 		$5.48M Buy
11,780
+6,916
+142% +$3.49M 0.02% 736
2020
Q2 		$2.85M Buy
4,864
+2,804
+136% +$957K 0.01% 1031
2020
Q1 		$300K Buy
2,060
+564
+38% +$98.6K ﹤0.01% 2012
2019
Q4 		$214K Buy
1,496
+60
+4% +$4.39K ﹤0.01% 2161
2019
Q3 		$57K Buy
1,436
+976
+212% +$71K ﹤0.01% 2148
2019
Q2 		$47K Buy
+460
New +$54.2K ﹤0.01% 2257

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Advisers's MRSN Position: Q4 2025 in Review

Two Sigma Advisers sold out of Mersana Therapeutics (MRSN) in Q4 2025, closing a stake of 40,640 shares — an estimated $315K sold.

Two Sigma Advisers first reported a position in MRSN in Q2 2019 and held it in 26 quarters. The position peaked at $13M in Q4 2020. 51 funds tracked by Wall St. Rank hold MRSN as of Q4 2025.

  • Two Sigma Advisers reported no remaining Mersana Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 40,640 Mersana Therapeutics shares in Q4 2025, an estimated $315K.
  • Two Sigma Advisers first reported a position in Mersana Therapeutics in Q2 2019 and held it in 26 quarters.
  • Two Sigma Advisers's Mersana Therapeutics position peaked at $13M in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.